0.1715
price down icon14.25%   -0.0285
after-market Handel nachbörslich: .17 -0.0015 -0.87%
loading
Schlusskurs vom Vortag:
$0.20
Offen:
$0.1928
24-Stunden-Volumen:
6.75M
Relative Volume:
0.65
Marktkapitalisierung:
$23.25M
Einnahmen:
$1.73M
Nettoeinkommen (Verlust:
$-23.50M
KGV:
-0.7853
EPS:
-0.2184
Netto-Cashflow:
$-19.37M
1W Leistung:
-11.14%
1M Leistung:
-15.39%
6M Leistung:
-72.57%
1J Leistung:
-68.28%
1-Tages-Spanne:
Value
$0.17
$0.1928
1-Wochen-Bereich:
Value
$0.17
$0.2059
52-Wochen-Spanne:
Value
$0.17
$0.94

VolitionRX Ltd Stock (VNRX) Company Profile

Name
Firmenname
VolitionRX Ltd
Name
Telefon
646 650 1351
Name
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Name
Mitarbeiter
37
Name
Twitter
@VolitionRx
Name
Nächster Verdiensttermin
2026-03-31
Name
Neueste SEC-Einreichungen
Name
VNRX's Discussions on Twitter

Compare VNRX vs TMO, DHR, IDXX, A, WAT

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
VNRX icon
VNRX
VolitionRX Ltd
0.1715 23.25M 1.73M -23.50M -19.37M -0.2184
TMO icon
TMO
Thermo Fisher Scientific Inc
491.46 182.57B 44.56B 6.72B 6.29B 17.74
DHR icon
DHR
Danaher Corp
191.12 135.26B 24.57B 3.60B 5.26B 5.051
IDXX icon
IDXX
Idexx Laboratories Inc
569.55 45.24B 4.30B 1.06B 1.04B 13.08
A icon
A
Agilent Technologies Inc
115.48 32.63B 7.07B 1.29B 993.00M 4.5355
WAT icon
WAT
Waters Corp
304.24 29.85B 3.17B 642.63M 516.49M 10.77

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet H.C. Wainwright Buy
2023-02-01 Herabstufung The Benchmark Company Buy → Hold
2022-02-17 Fortgesetzt Cantor Fitzgerald Overweight
2021-03-10 Eingeleitet Cantor Fitzgerald Overweight
2018-05-16 Eingeleitet Maxim Group Buy
2018-05-14 Bestätigt The Benchmark Company Buy
2016-09-07 Bestätigt Rodman & Renshaw Buy
2016-02-01 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten

pulisher
Apr 04, 2026

VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks

Apr 04, 2026
pulisher
Apr 04, 2026

VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK

Apr 04, 2026
pulisher
Apr 03, 2026

VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus

Apr 03, 2026
pulisher
Apr 03, 2026

VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo

Apr 03, 2026
pulisher
Apr 03, 2026

VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 03, 2026
pulisher
Apr 03, 2026

VolitionRX Q4 Earnings Call Highlights - Defense World

Apr 03, 2026
pulisher
Apr 02, 2026

VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Apr 02, 2026
pulisher
Apr 02, 2026

VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus

Apr 02, 2026
pulisher
Apr 02, 2026

VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut - TipRanks

Apr 02, 2026
pulisher
Apr 02, 2026

VolitionRX (VNRX) Sees Target Price Cut Despite Maintained Buy R - GuruFocus

Apr 02, 2026
pulisher
Apr 02, 2026

VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart

Apr 02, 2026
pulisher
Apr 01, 2026

VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan

Apr 01, 2026
pulisher
Apr 01, 2026

Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results By Investing.com - Investing.com South Africa

Apr 01, 2026
pulisher
Apr 01, 2026

Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results - Investing.com

Apr 01, 2026
pulisher
Apr 01, 2026

VolitionRx Limited Q4 2025 Earnings Call Summary - finance.yahoo.com

Apr 01, 2026
pulisher
Apr 01, 2026

VolitionRx : Corporate Presentation April 2026 - marketscreener.com

Apr 01, 2026
pulisher
Apr 01, 2026

VNRX|VolitionRX Ltd|Price:0.200|Chg%:-0.00 - TradingKey

Apr 01, 2026
pulisher
Apr 01, 2026

VolitionRX's Nu.Q Cancer Reimbursement Decision in Q4 2026 Could Unlock Commercial Licensing Momentum Amid Dilution Risks - Bitget

Apr 01, 2026
pulisher
Apr 01, 2026

VolitionRx secures €2M in Belgian government financing By Investing.com - Investing.com South Africa

Apr 01, 2026
pulisher
Apr 01, 2026

Volitionrx Ltd earnings beat, revenue fell short of estimates By Investing.com - Investing.com India

Apr 01, 2026
pulisher
Apr 01, 2026

Volitionrx Ltd earnings beat, revenue fell short of estimates - Investing.com UK

Apr 01, 2026
pulisher
Apr 01, 2026

VolitionRX: Q4 Earnings Snapshot - theheraldreview.com

Apr 01, 2026
pulisher
Mar 31, 2026

VolitionRX (VNRX) Rating Maintained as Buy by D. Boral Capital | - GuruFocus

Mar 31, 2026
pulisher
Mar 31, 2026

VolitionRx (NYSE: VNRX) details going concern risk, funding needs and Nu.Q® rollout - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update - finance.yahoo.com

Mar 31, 2026
pulisher
Mar 31, 2026

VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo

Mar 31, 2026
pulisher
Mar 31, 2026

VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus

Mar 31, 2026
pulisher
Mar 31, 2026

Belgian agencies give VolitionRx €2M to advance tests for poorer countries - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

VolitionRx biomarkers show elevation in trauma patients study By Investing.com - Investing.com South Africa

Mar 31, 2026
pulisher
Mar 30, 2026

VolitionRx biomarkers show elevation in trauma patients study - Investing.com

Mar 30, 2026
pulisher
Mar 26, 2026

A blood test before lung surgery helped flag higher-risk patients - stocktitan.net

Mar 26, 2026
pulisher
Mar 25, 2026

VolitionRx to outline 2025 results and milestones on April 1 - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

VolitionRx Limited (VNRX) Stock: Rallies on Promising Multi-Cancer Early Detection Breakthrough - parameter.io

Mar 25, 2026
pulisher
Mar 25, 2026

Blood test detects 95% of stage I and II cancers in blinded study - Stock Titan

Mar 25, 2026
pulisher
Mar 23, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 23, 2026
pulisher
Mar 21, 2026

VNRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026
pulisher
Mar 19, 2026

VolitionRx (NYSE: VNRX) CCO shares withheld and cancelled for RSU taxes - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Tax withholding reduces VolitionRx (NYSE: VNRX) secretary’s share count - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

VolitionRx (VNRX) CSO uses 5,310 shares to cover tax bill - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

VolitionRx (VNRX) GC has 7,003 shares cancelled for tax withholding - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

In today's session, these stocks are experiencing unusual volume. - ChartMill

Mar 19, 2026
pulisher
Mar 18, 2026

VNRX Receives Unchanged 'Buy' Rating from D. Boral Capital | VNR - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

VolitionRX Ltd (VNRX) Stock Price, Quote, News & History - Benzinga

Mar 18, 2026
pulisher
Mar 18, 2026

VolitionRx Limited (VNRX) Stock: Jumps on World-First Cancer DNA Isolation Breakthrough - parameter.io

Mar 18, 2026
pulisher
Mar 18, 2026

These stocks are the most active in today's session - ChartMill

Mar 18, 2026
pulisher
Mar 18, 2026

Stock Market Volume Leaders: Nasdaq, NYSE, and NYSE American Trading ActivityNews and Statistics - IndexBox

Mar 18, 2026
pulisher
Mar 18, 2026

Aug Drivers: What is the cash position of VolitionRx Limited2026 Biggest Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 18, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 18, 2026
pulisher
Mar 18, 2026

VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Discovery - Blockonomi

Mar 18, 2026
pulisher
Mar 18, 2026

VolitionRx (VNRX) Stock Soars 70% on Liquid Biopsy Breakthrough - parameter.io

Mar 18, 2026
pulisher
Mar 18, 2026

VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Detection Method - MoneyCheck

Mar 18, 2026

Finanzdaten der VolitionRX Ltd-Aktie (VNRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

VolitionRX Ltd-Aktie (VNRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Reynolds Cameron John
President and CEO
Oct 14 '25
Buy
0.51
110,000
56,100
2,534,847
Innes Guy Archibald
Director
Oct 14 '25
Buy
0.51
96,153
49,038
1,062,967
STILL TIMOTHY I
Director
Oct 14 '25
Buy
0.51
48,076
24,519
1,535,458
Reynolds Cameron John
President and CEO
Sep 12 '25
Buy
0.66
15,000
9,885
2,624,847
Innes Guy Archibald
Director
Aug 05 '25
Buy
0.64
78,125
50,000
966,814
Reynolds Cameron John
President and CEO
Aug 05 '25
Buy
0.64
78,125
50,000
2,609,847
Reynolds Cameron John
President and CEO
Jun 12 '25
Buy
0.59
12,500
7,372
2,331,722
Innes Guy Archibald
Director
Jun 03 '25
Buy
0.54
20,000
10,772
888,689
Micallef Jacob Vincent
Chief Scientific Officer
May 19 '25
Buy
0.43
50,000
21,500
426,033
Reynolds Cameron John
President and CEO
May 19 '25
Buy
0.44
20,000
8,730
2,319,222
DGX DGX
$198.02
price up icon 0.17%
LH LH
$273.72
price up icon 0.36%
MTD MTD
$1,259.94
price down icon 1.11%
IQV IQV
$173.26
price up icon 0.50%
$207.98
price up icon 2.35%
WAT WAT
$304.24
price up icon 1.45%
Kapitalisierung:     |  Volumen (24h):